Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11045555
Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles
granted -
US 11046959
Compositions comprising TALENs and methods of treating HIV
granted -
US 11046755
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
granted -
US 11041023
Chimeric antigen receptors for phagocytosis
granted -
US 11040959
Diprovocims: a new and potent class of TLR agonists
granted -
US 11040027
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
granted -
US 11040091
Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
granted -
US 11040125
Neurotrophic factor carrier, method for producing the same, and method for regenerating a nerve using the same
granted -
US 11033496
Nanoparticles for delivery of chemopreventive agents
granted -
US 11033560
Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors
granted -
US 11033584
Targeted replacement of endogenous T cell receptors
granted -
US 11033588
Compositions for treating inflammation and uses thereof
granted -
US 11033605
Methods of promoting angiogenesis in tissue with fibromodulin
granted -
US 11033601
Selective inhibition of V1b for treating fatty liver
granted -
US 11034662
Substituted phenothiazines as mitochondrial agents
granted -
US 11033659
Nanofiber structures and methods of synthesis and use thereof
granted -
US 11034933
Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection
granted -
US 11034739
Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
granted -
US 11033635
Antibody-STING agonist conjugates and their use in immunotherapy
granted -
US 11033611
Compositions and methods for administration of an enzyme to a subject's airway
granted -
US 11033587
Administration of cells and cellular extracts for rejuvenation
granted -
US 11033612
Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
granted -
US 11033640
Enteric CT contrast material based on low-z atoms
granted -
US 11028369
Induced extended pluripotent stem cells, method of making and using
granted -
US 11028128
Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments
granted -
US 11028412
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11028362
Decellularized human amniotic membrane for cell delivery, cell culture and inflammation prevention
granted -
US 11026960
Esters of 2-deoxy-monosaccharides with anti proliferative activity
granted -
US 11028162
Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties
granted -
US 11028129
Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions
granted -
US 11028083
Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
granted -
US 11026889
Polymeric drug delivery systems for treatment of disease
granted -
US 11021497
Compositions and methods for synthesis of phosphorylated molecules
granted -
US 11020488
Pyrroloquinolin compounds and methods of using same
granted -
US 11021469
Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
granted -
US 11021517
Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery
granted -
US 11020436
Multipotent and immunocompatible stem cell concentrate
granted -
US 11021506
Thiosaccharide mucolytic agents
granted -
US 11020345
Nanostraw devices and methods of fabricating and using the same
granted -
US 11020463
Method of determining cellular protein homeostasis
granted -
US 11020391
CRMP2 sumoylation inhibitors and uses thereof
granted -
US 11020409
Broad antiviral therapy with membrane modifying oxysterols
granted -
US 11021706
Antisense antibacterial compounds and methods
granted -
US 11022602
Antibiotic-based conjugates and methods of use thereof
granted -
US 11020470
Virus-like particles
granted -
US 11021545
Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
granted -
US 11020383
Methods for the treatment of cancer metastasis
granted -
US 11021523
Cyanobacteriochromes active in the far-red to near-infrared
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory